PROM1 and neoplasm: In the present study, flow cytometry was used to identify CD133 antigen-positive expression in tumor cells derived from two subtypes of cells, and demonstrated that in CD133+ cell-induced tumors, the percentage of CD133+ cells was 2.47±0.67%, similar to the CD133+ percentage obtained from human brain tumors during the initial surgery (2.31±0.57%).